Zheng Quan Zhi Xing·2025-08-13 16:24Company Overview - Haisco Pharmaceutical Group Co., Ltd. is a diversified and specialized pharmaceutical group engaged in new drug research and development, manufacturing, and marketing [1][3] - The company has a registered capital of 1,119,917,970 RMB and is listed on the Shenzhen Stock Exchange under the stock code 002653 [1][2] Business Operations - The company operates in various segments including anesthesia, parenteral nutrition, antiemetics, hepatobiliary digestion, antibiotics, and cardiovascular products, with over 40 product varieties [1][3] - Key commercialized products include Haisco's proprietary drugs such as环泊酚注射液 (Haisco's new intravenous anesthetic), 苯磺酸克利加巴林胶囊 (for neuropathic pain), and 考格列汀片 (for type 2 diabetes) [3][6][7] Financial Performance - The company reported revenues of 372,134.92 million RMB in 2024, with a net profit of 39,545.52 million RMB [16] - The gross profit margin for 2024 was 70.29%, showing a slight decrease from previous years [18] Research and Development - The company has several innovative drugs in the pipeline, including HSK31679 for metabolic dysfunction-related fatty liver disease and HSK31858 for bronchiectasis [10][11] - Haisco's R&D investment has been significant, with expenditures of 100,094.35 million RMB in 2024, representing 26.90% of total revenue [24] Market Position and Strategy - Haisco aims to strengthen its market position through continuous innovation and the introduction of new products, particularly in the high-demand therapeutic areas [1][3] - The company is also focusing on expanding its presence in international markets, having submitted NDA for环泊酚注射液 to the FDA [5][23] Regulatory Environment - The company is subject to stringent regulatory requirements for drug approval and production, which can impact its operational efficiency and market entry timelines [27][28] - Haisco has obtained necessary licenses and certifications for its operations, but must continuously meet regulatory standards to maintain its market position [28]